Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


New CCC19 Data Offer Insights on COVID Treatments for People with Cancer


 
Jeremy Warner, MD, MS

Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.

The data on 2,186 adults in the United States by the COVID-19 and Cancer Consortium (CCC19) published July 22 in Cancer Discovery is the largest cancer-specific observational study to date of treatments purported to improve COVID-19 outcomes. The data were published shortly after a keynote address by Solange Peters, MD, PhD, president of the European Society for Medical Oncology and one of the study's lead authors, at the American Association for Cancer Research Virtual Meeting: COVID-19 and Cancer.

In this updated report from CCC19, the consortium's researchers confirm and expand upon earlier observations that there was broad use of unproven COVID-19 therapies, almost all of which were outside of clinical trials.

The steroid dexamethasone lowered the death rate among critically ill patients, according to data from the RECOVERY trial in the United Kingdom, but the CCC19 data indicate an association with increased mortality among cancer patients. In the CCC19 analysis, patients receiving high-dose corticosteroids with any other potential COVID-19 treatment were more than twice as likely to die, as compared to patients treated with other medications or patients not requiring any treatment. There were very small numbers of patients treated just with steroids, making analysis of steroids in isolation difficult.

"There is so much enthusiasm about dexamethasone, but our findings in a relatively small subgroup suggest that steroids could be associated with increased mortality in the cancer population," said Jeremy Warner, MD, MS, associate professor Medicine and Biomedical Informatics at Vanderbilt University, the study's corresponding author. "This does have some rational explanation, since cancer is already an immunocompromised state and steroids could potentially make things worse. The RECOVERY trial is the first to show a survival benefit for any treatment of COVID-19, but that study just published in The New England Journal of Medicine does not provide details for the subgroup of patients with cancer."

Remdesivir, which was primarily available as a clinical trial option, was associated with a lower mortality rate when compared to patients receiving any other potential COVID-19 treatment. Black patients were half as likely to receive Remdesivir as white patients.

"Our study reinforces the finding that most COVID-19 treatment occurs outside the context of a formal clinical trial," Warner said. "The exception to this was the drug Remdesivir, which was given mostly through the clinical trial setting. It appears that Black patients were underrepresented in the clinical trials of Remdesivir, likely due to reasons other than purely clinical factors. The unfortunate conclusion is that racial disparities in access to clinical trials continue to exist, and one of our recommendations is that the necessary steps to address such disparities need to be accelerated, especially given that Black patients and other people of color appear to be taking the brunt of the COVID-19 pandemic."

This is the second study and release of data by CCC19. While the mortality rate among cancer patients affected by COVID-19 was 13% in the prior study of 928 patients, the rate was 16% in the newly published study, which involved 2,186 patients.

Patients on the West Coast were more likely to have received Remdesivir and less likely to have been treated with hydroxychloroquine, which a number of studies have shown to be an ineffective treatment that is associated with higher mortality. One reason could be that the number of cases increased on the West Coast after more information was known about the benefits and risks of the two treatments, Warner said.

"We can be much more definitive in stating the risk and ineffectiveness of hydroxychloroquine with this enhanced analysis," said co-senior author, Gary Lyman, MD, MPH, professor of Public Health Sciences and Clinical Research at Fred Hutchinson Cancer Research Center in Seattle. "This higher mortality association is despite what appears to be rational decision making, such as less utilization of this drug in patients with cardiovascular comorbidities."

Vanderbilt coauthors on the study included Samuel Rubenstein, MD, Brendan J. Lee, Brian Rini, MD, Ingram Professor of Cancer Research, Chih-Yuan Hsu, PhD, Sanjay Mishra, PhD, and Yu Shyr, PhD, the Harold L. Moses Chair in Cancer Research and chair of the Department of Biostatistics.

Share:

 

Email Print

 

More Grand Rounds:

 

ACEP Applauds Removal of X-waiver, Expanding Medication-assisted Treatment for Opioid Use Disorder

Read More

Youtube Announces A New Team, Led By Dr. Garth Graham, To Bring More Authoritative, Engaging Health Content To The Platform

YouTube is unveiling a new health partnerships team to address the evolving digital health needs of consumers and the desire for clinicians to be able to communicate beyond the exam room.

Read More

Centerstone Earns Five-Year Reaccreditation from American Association of Suicidology

Centerstone, a national leader in behavioral healthcare, has received a five-year reaccreditation from the American Association of Suicidology (AAS) for its Crisis Services line of care.

Read More

Heritage Group Launches $300 Million Oversubscribed Third Fund

Heritage Group Launches $300 Million Oversubscribed Third Fund

Backed by Leading National Healthcare Organizations, Heritage Group Utilizes Strategic Private Equity Investing Model to Address Healthcare's Greatest Challenges

Read More

Nashville's Specialty Dental Brands Garners $107 Million in New Financing

Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to healthcare services and life sciences companies worldwide, announced the closing of a $107 million senior credit facility to Specialty Dental Brands ("SDB" or "the Company") a dental services organization headquartered in Nashville, which focuses on pediatric dentistry, orthodontics, and oral surgery.

Read More

Onlife Health Honored with Nation's Best and Brightest in Wellness® Award for Fourth Consecutive Year

Onlife Health, a GuideWell Company with 23 years of experience in delivering well-being-engagement solutions, today announced it has received the Fall 2020 Nation's Best and Brightest in Wellness® award from the National Association for Business Resources (NABR).

Read More

Covenant Physician Partners Announces Goran Dragolovic to Succeed Lew Little as President and CEO

Covenant Physician Partners (Covenant), a rapidly growing physician services company, announced today that Goran Dragolovic will succeed Lew Little as President and Chief Executive Officer, effective January 11, 2021.

Read More

Integrated Oncology Network Announces Strategic Partnership with Southwest Urology

Integrated Oncology Network Announces Strategic Partnership with Southwest Urology

Cleveland multi-specialty platform pivotal to strategic growth of nationwide networks

Read More

Simplify ASC Acquires PhyBus Revenue Services

Ambulatory Surgery Center operators have a unique hybrid offering to leverage.

Read More

Ascend Federal Credit Union Donates $50,000 to Monroe Carell Jr. Children's Hospital at Vanderbilt

Ascend Federal Credit Union Donates $50,000 to Monroe Carell Jr. Children's Hospital at Vanderbilt

Ascend Federal Credit Union, the largest credit union in Middle Tennessee, today announced a donation of $50,000 to Monroe Carell Jr. Children's Hospital at Vanderbilt.

Read More

Patsy Powers and Brent Hill to lead Waller's Nationally Recognized Healthcare Industry Team

Patsy Powers and Brent Hill to lead Waller's Nationally Recognized Healthcare Industry Team

Attorneys enhance leadership roles at one of the nation's largest healthcare law firms

Read More

Skylight Health Announces Closing of Tennessee Clinic with $2.2 Million in Revenue and Positive EBITDA

Skylight Health Group Inc (CSE:SHG; OTCQX: CBIIF) ("SHG" or the "Company"), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce that it has closed on the acquisition of Healthcare Resources Management LLC ("HRM") which operates Perimeter Pain and Primary Clinic ("Perimeter") in Cookeville, Tennessee.

Read More

Michael Christie, MD, Receives 2020 AAHKS Humanitarian Award

Michael Christie, MD, Receives 2020 AAHKS Humanitarian Award

Michael Christie, MD, orthopedic surgeon at Southern Joint Replacement Institute and TriStar Centennial Medical Center, was awarded the 2020 Humanitarian Award from the American Association of Hip and Knee Surgeons (AAHKS).

Read More

VUMC Acquires Tennova's Shelbyville and Tullahoma Hospitals from CHS and is Now Partnered with Tennova Healthcare-Clarksville Hospital

Read More

BlueCross Foundation Providing $1.75 Million to Tennessee Food Banks

BlueCross Foundation Providing $1.75 Million to Tennessee Food Banks

$5 million given this year to address food insecurity issues related to the COVID-19 pandemic

Read More

emids Taps Industry Veteran Sriraman Nagarajan to Lead Life Sciences Business Unit

emids Taps Industry Veteran Sriraman Nagarajan to Lead Life Sciences Business Unit

emids, a leader in digital engineering and transformation solutions to the healthcare industry, today announced the appointment of Sriraman Nagarajan as President of its Life Sciences business unit.

Read More

Alzheimer's Foundation of America: Congress Approves Historic $3.12 Billion Appropriation for Federal Alzheimer's Research Funding

As part of its end of year spending package, Congress approved passage of the Health and Human Services (HHS) budget for fiscal year (FY) 2021, which is expected to be signed by the President, with an additional $300 million designated for Alzheimer's disease research at the National Institutes for Health (NIH)-- bringing federal funding to find an Alzheimer's cure to a total of $3.12 billion.

Read More

Sarah Cannon promotes Melissa Johnson, MD, to Program Director, Lung Cancer Research

Sarah Cannon promotes Melissa Johnson, MD, to Program Director, Lung Cancer Research

Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research. In her new role, Dr. Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.

Read More

Very Real Help Announces Grant from the National Institute on Drug Abuse

Very Real Help (VRH), a company developing a novel mental health application, announced today a $206,000 grant from the National Institute on Drug Abuse to use their groundbreaking peer-support mental health platform as a clinical research tool to improve treatment for individuals living with opioid use disorder.

Read More

THE HUFF PROJECT DONATES $35,000 TO VANDERBILT-INGRAM CANCER CENTER

THE HUFF PROJECT DONATES $35,000 TO VANDERBILT-INGRAM CANCER CENTER

Gift to Help Fund Development of Lung Cancer Education Tool by VUMC Physician

Read More

 
 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: